Developers: | Biosense Webster |
Date of the premiere of the system: | September 2022 |
Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Announcement of catheter for detailed diagnosis of arrhythmia
Johnson & Johnson-owned Biosense Webster announced on September 6, 2022, the release of the Octaray arrhythmia mapping catheter with TRUEref technology. It is powered by the company's Carto 3 Version 7 system.
The catheter has eight splines with the ability to choose the optimal distance between the electrodes, the press release said. This provides a shorter and more efficient mapping time compared to the Pentaray catheter. Increasing efficiency and speed can reduce the total time of the ablation procedure, according to the company.
Octaray can display arrhythmias in any chamber to quickly obtain accurate information before the catheter ablation procedure. TRUEref technology reduces the influence of signals in the far zone. It helps to accurately identify breaks in the areas of the lesion and give them a more accurate characteristic.
With more splines and electrodes, increased coverage area and improved signal quality with the Octaray diagnostic catheter, you can better understand the anatomy and behavior of the heart chamber of interest, said Amit Tosani, director of the Division of Cardiac Electrophysiology at Allegheny Health Network. The catheter not only makes it possible to map the heart more accurately and efficiently, but also provides more effective therapy for a particular patient. |
Building on Biosense Webster's three decades of leadership in cardiac ablation science and technology, we are proud to introduce the new Octaray catheter with TRUEref technology as the newest mapping tool for electrophysiologists USA in and out of the region, " EMEA said Michael Bodner, Biosense Webster President worldwide. With shorter and more efficient mapping times, the catheter benefits both the patient and the physician, allowing for shorter procedure times while providing greater accuracy and detail. |
Octaray with TRUEref technology is available throughout EMEA and the United States.[1]